• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by ResMed Inc.

    4/1/26 5:30:15 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care
    Get the next $RMD alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001186102
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ResMed INC
    SEC File Number
    001-15317
    Address of Issuer
    9001 Spectrum Center Blvd
    SAN DIEGO
    CALIFORNIA
    92123
    Phone
    858-746-2400
    Name of Person for Whose Account the Securities are To Be Sold
    Peter C Farrell
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Merrill Lynch
    2049 Century Park East, Ste 1200
    Los Angeles � CA � 90067
    20004499204444895904/01/2026
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common11/11/2014Stock OptionPeter C FarrellCheckbox not checked189011/11/2014Cash
    Common11/11/2015Stock OptionPeter C FarrellCheckbox not checked11011/11/2015Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Peter C Farrell
    9001 Spectrum Center Blvd
    San Deigo � CA � 92123
    Common01/07/20262000497580
    Peter C Farrell
    9001 Spectrum Center Blvd
    San Deigo � CA � 92123
    Common02/04/20262000502540
    Peter C Farrell
    9001 Spectrum Center Blvd
    San Deigo � CA � 92123
    Common03/04/20262000520360

    144: Remarks and Signature

    Remarks
    Date of Notice
    04/01/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/12/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    PETER C FARRELL

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $RMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RMD

    DatePrice TargetRatingAnalyst
    4/15/2026Overweight
    Analyst
    12/16/2025$275.00Outperform → Neutral
    Robert W. Baird
    9/18/2025$330.00Buy
    Citigroup
    9/2/2025Hold → Outperform
    CLSA
    7/16/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    7/15/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    3/19/2025$280.00Overweight
    Morgan Stanley
    3/19/2025Overweight
    Morgan Stanley
    More analyst ratings

    $RMD
    SEC Filings

    View All

    SEC Form SD filed by ResMed Inc.

    SD - RESMED INC (0000943819) (Filer)

    5/26/26 4:30:09 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by ResMed Inc.

    8-K - RESMED INC (0000943819) (Filer)

    4/30/26 4:10:25 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - RESMED INC (0000943819) (Filer)

    4/30/26 4:06:30 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

    Noctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit

    6/3/26 7:40:36 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

    SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has completed its acquisition of Noctrix Health, Inc., a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders. The acquisition expands Resmed's clinical sleep health portfolio into an adjacent area of significant unmet need — the treatment of Restless Legs Syndrome (RLS), the third most prevalent sleep disorder.1,2 For Noctrix Health, joining Resmed brings an opportunity to scale its innovation, expand patient access, and accelerate impact fo

    6/1/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference

    SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46th Annual William Blair Growth Stock Conference in Chicago, IL on Tuesday, June 2, 2026. Resmed's webcast presentation will begin at approximately 4:40 p.m. (Central Time). More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following ninety (90) days. About ResmedResmed (

    5/19/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)

    4 - RESMED INC (0000943819) (Issuer)

    6/3/26 3:45:27 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    5/11/26 7:33:48 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Bloomer Aaron

    3 - RESMED INC (0000943819) (Issuer)

    5/4/26 6:05:55 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on ResMed

    Analyst initiated coverage of ResMed with a rating of Overweight

    4/15/26 11:26:08 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded ResMed from Outperform to Neutral and set a new price target of $275.00

    12/16/25 8:57:57 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Citigroup initiated coverage on ResMed with a new price target

    Citigroup initiated coverage of ResMed with a rating of Buy and set a new price target of $330.00

    9/18/25 8:44:39 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Financials

    Live finance-specific insights

    View All

    Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

    Noctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit

    6/3/26 7:40:36 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026

    Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8%GAAP income from operations increased 17%; non-GAAP income from operations up 18%GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended March 31, 2026.

    4/30/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026

    SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com•Date:1:30 p.m. PT / 4:30 p.m. ET•Time:London, Thursday, April 30, 2026, 9:30 p.m. BST•International:Sydney, Friday, May 1, 2026, 6:30 a.m. AEST    Please note, Resmed does not use outside phone lines t

    4/1/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Leadership Updates

    Live Leadership Updates

    View All

    Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor

    SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.  "After 27 years with Resmed, including 20 as CFO, Brett leaves an outstanding legacy of disciplined leadership and trusted partnership," said Mick Farrell, Chairman and CEO of Resmed. "Brett's leadership has helped guide Resmed through significant growth and transformation, while keeping a clear focus on long-term value creat

    4/30/26 4:10:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Names Salli Schwartz as Chief Investor Relations Officer

    SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

    4/21/25 5:00:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/23 1:36:52 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 5:05:17 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 8:32:59 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care